Vistagen’s positive PhIII for social anxiety nasal spray pushes stock price up 1,000+%

San Francisco-based Vistagen saw its stock soar more than 1,000% at one point on Monday after unveiling positive topline results from a Phase III trial showing its nasal spray helped adults with social anxiety disorder.

The Phase III PALISADE-2 trial of 140 subjects met its primary endpoint, with the experimental…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks